The Latest
-
Spencer Platt via Getty Images
With compounders out of the way, Lilly and Novo go after each other
The two obesity leaders are pulling on all levers to stay on top of the market.
-
Stock via Getty Images
Is pharma ready to let go of animal testing?
Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.
-
Stock via Getty Images
Q&ACan real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.
-
Courtesy of Johnson & Johnson
J&J scores FDA OK for immune drug touted as future blockbuster
The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.
-
Stock via Getty Images
US backlash against mRNA vaccines could hinder scientific progress
U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.
-
Andrew Harnik via Getty Images
Is the FDA headed for a major reorganization?
A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture.
-
Permission granted by Flagship Pioneering
Flagship’s latest venture reflects more than 25 years of leaping into the unknown
A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.
-
Sarah Silbiger via Getty Images
FDA’s job cuts paint mixed picture for drugmakers’ R&D plans
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
-
Stock via Getty Images
What’s being cut at NIH
A look at the government’s far-reaching rollback in research grants so far.
-
Permission granted by Bristol Myers Squibb
Will Cobenfy’s clinical stumble derail a once-predicted rise?
BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.
-
Kevin Dietsch via Getty Images
Trump reveals pharma reform priorities in drug pricing executive order
The order takes aim at fixing the IRA’s “pill penalty,” as well as PBM reform and other attempts to lower drug prices.
-
aprott via Getty Images
Beyond the drug: Closing the knowledge gap for injectable diabetes meds
As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs.
-
wildpixel via Getty Images
Genetic breakthroughs could point pharma to a long COVID drug
The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.
-
hapabapa via Getty Images
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
-
Stock via Getty Images
How a scrapped Pfizer drug became a winner for SpringWorks
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
-
Stock via Getty Images
A big moment is coming for psychedelics
Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.
-
Sedat Suna via Getty Images
Novartis scores NFL deal to tackle health outcomes
The non-traditional marketing approach comes amid a potential crackdown on TV drug ads.
-
Anna Moneymaker via Getty Images
Deep DiveHHS layoffs may be illegal, legal experts say
The federal health department sidestepped normal procedures as it laid off 10,000 employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.
-
Stock via Getty Images
Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub
Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments.
-
Stephen Maturen via Getty Images
The fallout from UnitedHealth’s CEO slaying
Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.
-
Stock via Getty Images
‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?
The biotech market is taking a beating amid Trump’s turbulent economic policies.
-
Getty Images via Getty Images
Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model
Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.
-
Stock via Getty Images
Pharma’s US manufacturing moment: Where companies are making the biggest moves
The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.
-
Chip Somodevilla via Getty Images
Trump’s tariff tirade and sudden calm keep Big Pharma on its toes
A wild ride in an escalating trade war has torn at Big Pharma’s shares while global markets flag in the back-and-forth winds.
-
Kevin Frayer via Getty Images
US risks losing biotech edge to China, report warns
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.
